Impact of Probiotics on Children with Acute Gastroenteritis: Results from an Umbrella Meta-Analysis.

J Integr Complement MedMay 4, 2026 (epub)

Sen Fan, Xianchun Mao, Ranran Li

✦ AI-curated · Sources linked

In 30 seconds

This umbrella meta-analysis assessed probiotic efficacy for acute gastroenteritis in children, synthesising 36 meta-analyses with 107,541 participants. Probiotics were associated with potential reductions in diarrhea duration, vomiting, fever, hospital stay, stool frequency, and diarrhea on selected post-treatment days, as well as possible prevention of gastroenteritis. Effects varied by probiotic strain and, for some outcomes, by dose and treatment duration. The authors identified several strains with the strongest overall symptom efficacy, but the abstract does not report pooled effect sizes for these outcomes.

Key findings

  • The umbrella review included 36 meta-analyses and 107,541 participants.
  • Probiotics may reduce diarrhea duration, vomiting, fever, hospital stay, and stool frequency in children with acute gastroenteritis.
  • Effects were strain-specific; dose and treatment duration influenced some outcomes, with variation across strains and clinical settings.
  • The authors identified S. boulardii CNCM I-745, L. rhamnosus GG, and several other strains or combinations as among the most effective.

Why it matters

The synthesis suggests that probiotics may offer benefits across several clinically relevant gastroenteritis outcomes in children, but it does not support treating probiotics as a uniform intervention. Strain, dose, duration, and care setting may affect results, so these distinctions matter when interpreting evidence and considering its applicability to clinical care.

What to keep in mind

The abstract provides no pooled effect estimates, and the findings combine prior meta-analyses whose results varied by strain, dose, duration, and clinical setting.

Source

Published in J Integr Complement Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.